# EDGAR Filing Document

**Accession Number:** 0000313212
**File Stem:** 0001999371-26-013828
**Filing Date:** 2026-6
**Character Count:** 3996
**Document Hash:** f06cc81d64174c51b843c613f2a2a8e4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-26-013828.hdr.sgml**: 20260630

**ACCESSION NUMBER**: 0001999371-26-013828

**CONFORMED SUBMISSION TYPE**: 497K

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260630

**DATE AS OF CHANGE**: 20260630

**EFFECTIVENESS DATE**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** T. Rowe Price International Funds, Inc.
- **CENTRAL INDEX KEY:** 0000313212

**ORGANIZATION NAME:**
- **EIN:** 521175211
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 497K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 002-65539
- **FILM NUMBER:** 261138688

**BUSINESS ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231
- **BUSINESS PHONE:** 410-345-2000

**MAIL ADDRESS:**
- **STREET 1:** 1307 POINT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE INTERNATIONAL FUNDS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE INTERNATIONAL TRUST
- **DATE OF NAME CHANGE:** 19900301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE INTERNATIONAL FUND INC
- **DATE OF NAME CHANGE:** 19890914

## Series and Classes Contracts Data

### T. Rowe Price Emerging Markets Stock Fund (Series ID: S000001496)

| Class ID   | Class Name                                        | Ticker Symbol   |
|:---|:---|:---|
| C000004015 | T. Rowe Price Emerging Markets Stock Fund         | PRMSX           |
| C000159129 | T. Rowe Price Emerging Markets Stock Fund-I Class | PRZIX           |
| C000219337 | T. Rowe Price Emerging Markets Stock Fund-Z Class | TRGZX           |

**T. Rowe Price Emerging Markets Stock Fund**

**T. Rowe Price Institutional Emerging Markets Equity Fund**

Supplement to Prospectus and Summary Prospectus dated January 1, 2026

**T. Rowe Price Health Sciences Fund**

**T. Rowe Price U.S. Equity Research Fund** 

**T. Rowe Price U.S. Large-Cap Core Fund**

Supplement to Prospectus and Summary Prospectus dated March 1, 2026

**T. Rowe Price Tax-Efficient Equity Fund**

Supplement to Prospectus and Summary Prospectus dated May 1, 2026

On June 25, 2026, the fund's shareholders approved a proposal to change the fund's diversification policy from diversified to nondiversified. The switch from diversified to nondiversified will become effective on July 1, 2026.

Accordingly, all of the following changes are effective July 1, 2026.

In the Summary Prospectus, and Sections 1 and 2 of the Prospectus, the disclosure under "Principal Investment Strategies" is supplemented as follows:

The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.

In the Summary Prospectus and Section 1 of the Prospectus, the disclosure under "Principal Risks" is supplemented as follows:

**Nondiversification:** As a nondiversified fund, the fund has the ability to invest a larger percentage of its assets in the securities of a smaller number of issuers than a diversified fund. As a result, poor performance by a single issuer could adversely affect fund performance more than if the fund were invested in a larger number of issuers. The fund's share price can be expected to fluctuate more than that of a similar fund that is more broadly diversified.

In Section 2 of the Prospectus, the disclosure under "Principal Risks" is supplemented as follows:

**Nondiversification:** Because the fund is nondiversified and thus can invest more of its assets in a smaller number of issuers, it is more exposed to the risks associated with an individual issuer than a fund that invests more broadly across many issuers. For example, poor performance by a single large holding of the fund would adversely affect the fund's performance more than if the fund were invested in a larger number of issuers.

The date of this supplement is June 30, 2026.

G78-041 6/30/26